Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.
Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson IF, Bratt J, van Vollenhoven RF; SWEFOT Trial Investigators Group. Saevarsdottir S, et al. Among authors: ernestam s. Ann Rheum Dis. 2011 Mar;70(3):469-75. doi: 10.1136/ard.2010.139212. Epub 2010 Dec 13. Ann Rheum Dis. 2011. PMID: 21149498 Clinical Trial.
In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.
Rezaei H, Saevarsdottir S, Forslind K, Albertsson K, Wallin H, Bratt J, Ernestam S, Geborek P, Pettersson IF, van Vollenhoven RF. Rezaei H, et al. Among authors: ernestam s. Ann Rheum Dis. 2012 Feb;71(2):186-91. doi: 10.1136/annrheumdis-2011-200038. Epub 2011 Sep 19. Ann Rheum Dis. 2012. PMID: 21930734 Clinical Trial.
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA, Neovius M, Nilsson JÅ, Petersson IF, Bratt J, van Vollenhoven RF, Ernestam S, Geborek P. Karlsson JA, et al. Among authors: ernestam s. Ann Rheum Dis. 2013 Dec;72(12):1927-33. doi: 10.1136/annrheumdis-2012-202062. Epub 2012 Nov 29. Ann Rheum Dis. 2013. PMID: 23196701 Clinical Trial.
Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.
Saevarsdottir S, Rezaei H, Geborek P, Petersson I, Ernestam S, Albertsson K, Forslind K, van Vollenhoven RF; SWEFOT study group. Saevarsdottir S, et al. Among authors: ernestam s. Ann Rheum Dis. 2015 Aug;74(8):1509-14. doi: 10.1136/annrheumdis-2013-204601. Epub 2014 Apr 4. Ann Rheum Dis. 2015. PMID: 24706006 Free PMC article. Clinical Trial.
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, Geborek P, Neovius M. Eriksson JK, et al. Among authors: ernestam s. Ann Rheum Dis. 2015 Jun;74(6):1094-101. doi: 10.1136/annrheumdis-2013-205060. Epub 2014 Apr 15. Ann Rheum Dis. 2015. PMID: 24737786 Free PMC article. Clinical Trial.
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Kastbom A, Forslind K, Ernestam S, Geborek P, Karlsson JA, Petersson IF, Saevarsdottir S, Klareskog L, van Vollenhoven RF, Lundberg K. Kastbom A, et al. Among authors: ernestam s. Ann Rheum Dis. 2016 Feb;75(2):356-61. doi: 10.1136/annrheumdis-2014-205698. Epub 2014 Dec 30. Ann Rheum Dis. 2016. PMID: 25550338 Free PMC article. Clinical Trial.
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, Chatzidionysiou K, Bratt J; Swefot study group. van Vollenhoven RF, et al. Among authors: ernestam s. Lancet. 2012 May 5;379(9827):1712-20. doi: 10.1016/S0140-6736(12)60027-0. Epub 2012 Mar 29. Lancet. 2012. PMID: 22464340 Clinical Trial.
44 results